{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Infection", "Psoriasis", "SARS-CoV-2", "Vaccination"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37378776", "DateCompleted": {"Year": "2023", "Month": "06", "Day": "30"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "30"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1007/978-3-031-28012-2_18"], "Journal": {"ISSN": "0065-2598", "JournalIssue": {"Volume": "1412", "PubDate": {"Year": "2023"}}, "Title": "Advances in experimental medicine and biology", "ISOAbbreviation": "Adv Exp Med Biol"}, "ArticleTitle": "The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.", "Pagination": {"StartPage": "339", "EndPage": "355", "MedlinePgn": "339-355"}, "Abstract": {"AbstractText": ["Since the outbreak of the COVID-19 pandemic in December 2019, scientists worldwide have been looking for a way to control this global threat. One of the most successful and practical solutions has been the development and worldwide distribution of the COVID-19 vaccines. However, in a small percentage of cases, vaccination can lead to de novo development or exacerbation of immune or inflammatory conditions such as psoriasis. Due to the immunomodulatory nature of this disease, people affected by psoriasis and other related skin conditions have been encouraged to receive COVID-19 vaccines, which are immunomodulatory by nature. As such, dermatological reactions are possible in these patients, and cases of onset, exacerbation or change in the type of psoriasis have been observed in patients administered with COVID-19 vaccines. Considering the rarity and minor nature of some of these cutaneous reactions to COVID-19 vaccination, there is a general consensus that the benefits of vaccination outweigh the potential risks of experiencing such side effects. Nevertheless, healthcare workers who administer vaccines should be made aware of the potential risks and advise recipients accordingly. Furthermore, we suggest careful monitoring for potentially deleterious autoimmune and hyperinflammatory responses using point-of-care biomarker monitoring."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Khanahmadi", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Khayatan", "ForeName": "Danial", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany."}, {"Identifier": [], "Affiliation": "Laboratory of Translational Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany."}, {"Identifier": [], "Affiliation": "Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil."}], "LastName": "Guest", "ForeName": "Paul C", "Initials": "PC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Hashemian", "ForeName": "Somayyeh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, Karaj, Iran."}, {"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Sahebkar", "ForeName": "Amirhossein", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Adv Exp Med Biol", "NlmUniqueID": "0121103", "ISSNLinking": "0065-2598"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "COVID-19 Vaccines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["prevention & control"], "DescriptorName": "COVID-19"}, {"QualifierName": ["adverse effects"], "DescriptorName": "COVID-19 Vaccines"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": [], "DescriptorName": "Psoriasis"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Vaccination"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "El Zowalaty ME,J\u00e4rhult JD (2020) From SARS to COVID-19: A previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans\u2013Call for a One Health approach. One Health 9:100124. https://doi.org/10.1016/j.onehlt.2020.100124", "ArticleIdList": ["10.1016/j.onehlt.2020.100124", "32195311", "7075990"]}, {"Citation": "Lai CC, Shih TP, Ko WC, et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924", "ArticleIdList": ["10.1016/j.ijantimicag.2020.105924", "32081636", "7127800"]}, {"Citation": "Kempuraj D, Selvakumar GP, Ahmed ME, et al. (2020) COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26(5\u20136):402\u2013414", "ArticleIdList": ["32684080", "10.1177/1073858420941476"]}, {"Citation": "Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations . Accessed October 18, 2022"}, {"Citation": "Lazarus JV, Wyka K, White TM, et al (2022) Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun 13(1):3801. https://doi.org/10.1038/s41467-022-31441-x", "ArticleIdList": ["10.1038/s41467-022-31441-x", "35778396", "9247969"]}, {"Citation": "Mushtaq HA, Khedr A, Koritala T, et al (2022) A review of adverse effects of COVID-19 vaccines. Infez Med. 30(1):1\u201310", "ArticleIdList": ["35350266", "8929726"]}, {"Citation": "Rahman MM, Masum MHU, Wajed S, Talukder A (2022) A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. Virusdisease 33(1):1\u201322. https://doi.org/10.1007/s13337-022-00755-1", "ArticleIdList": ["10.1007/s13337-022-00755-1", "35127995", "8806010"]}, {"Citation": "Chi WY, Li YD, Huang HC, Chan TEH, et al (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 29(1):82. https://doi.org/10.1186/s12929-022-00853-8", "ArticleIdList": ["10.1186/s12929-022-00853-8", "36243868", "9569411"]}, {"Citation": "Musumeci ML, Caruso G, Trecarichi AC, Micali G (2022) Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience. Dermatol Ther 35(1):e15177. https://doi.org/10.1111/dth.15177", "ArticleIdList": ["10.1111/dth.15177", "34699117"]}, {"Citation": "Piros \u00c9A, Cseprek\u00e1l O, G\u00f6r\u00f6g A, et al (2022) Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study. Dermatol Ther 35(5):e15408. https://doi.org/10.1111/dth.15408", "ArticleIdList": ["10.1111/dth.15408", "35218276", "9111760"]}, {"Citation": "Seirafianpour F, Pourriyahi H, Gholizadeh Mesgarha M, et al (2022) A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatol Ther 35(6):e15461. https://doi.org/10.1111/dth.15461", "ArticleIdList": ["10.1111/dth.15461", "35316551", "9111423"]}, {"Citation": "Tran TNA, Nguyen TTP, Pham NN, et al (2022) New onset of psoriasis following COVID-19 vaccination. Dermatol Ther 35(8):e15590. https://doi.org/10.1111/dth.15590", "ArticleIdList": ["10.1111/dth.15590", "35583958", "9348467"]}, {"Citation": "Chhabra N, C AG (2022) A case of de novo annular-plaque type psoriasis following Oxford-AstraZeneca COVID-19 vaccination. Curr Drug Saf.. https://doi.org/10.2174/1574886317666220613163327"}, {"Citation": "Shakoei S, Kalantari Y, Nasimi M, et al (2022) Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther 35(8):e15651. https://doi.org/10.1111/dth.15651", "ArticleIdList": ["10.1111/dth.15651", "35716105", "9349410"]}, {"Citation": "Brunasso AMG, Massone C (2020) Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. Dermatol Ther 33(4):e13495. https://doi.org/10.1111/dth.13695", "ArticleIdList": ["10.1111/dth.13695", "32458588", "7267078"]}, {"Citation": "Buhl T, Beissert S, Gaffal E, et al (2020) COVID-19 and implications for dermatological and allergological diseases. J Dtsch Dermatol Ges 18(8):815\u2013824", "ArticleIdList": ["32881343", "7461475"]}, {"Citation": "Drenovska K, Schmidt E, Vassileva S (2020) Covid-19 pandemic and the skin. Int J Dermatol 59(11):1312\u20131319", "ArticleIdList": ["32954488", "7537512", "10.1111/ijd.15189"]}, {"Citation": "Molaee H, Allahyari F, Emadi SN, et al (2021) Cutaneous manifestations related to the COVID-19 pandemic: a review article. Cutan Ocul Toxicol 40(2):168\u2013174", "ArticleIdList": ["34097555", "10.1080/15569527.2021.1919138"]}, {"Citation": "Krueger JG, Bowcock A (2005) Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2(Suppl 2):ii30-6. https://doi.org/10.1136/ard.2004.031120"}, {"Citation": "Hari G, Kishore A, Karkala SRP (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached? Eur J Pharmacol 929:175147. https://doi.org/10.1016/j.ejphar.2022.175147", "ArticleIdList": ["10.1016/j.ejphar.2022.175147", "35820531"]}, {"Citation": "Al-Beltagi M, Saeed NK, Bediwy AS (2022) COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol 12(4):200\u2013223", "ArticleIdList": ["36159097", "9350728", "10.5662/wjm.v12.i4.200"]}, {"Citation": "Rodr\u00edguez Y, Rojas M, Beltr\u00e1n S, et al (2022) Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 132:102898. https://doi.org/10.1016/j.jaut.2022.102898", "ArticleIdList": ["10.1016/j.jaut.2022.102898", "36041291", "9399140"]}, {"Citation": "Darmarajan T, Paudel KR, Candasamy M, et al (2022) Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation. Environ Sci Pollut Res Int 29(36):54072\u201354087", "ArticleIdList": ["35657545", "9163295", "10.1007/s11356-022-20984-7"]}, {"Citation": "World Health Organization; Global Report on Psoriasis (2016). https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1 . Accessed October 18, 2022"}, {"Citation": "Mayo Clinic; Psoriasis; Treatment; Oral or Injected Medications. https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355845#:~:text=Options%20include%20apremilast%20(Otezla)%2C,)%20and%20certolizumab%20(Cimzia) . Accessed October 19, 2022"}, {"Citation": "Di Lernia V (2020) Antipsoriatic treatments during COVID-19 outbreak. Dermatol Ther 33(4):e13345. https://doi.org/10.1111/dth.13345", "ArticleIdList": ["10.1111/dth.13345", "32223073", "7228205"]}, {"Citation": "Abdelmaksoud A, Goldust M, Vestita M (2020) Comment on \"COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action\". Dermatol Ther 33(4):e13360. https://doi.org/10.1111/dth.13360", "ArticleIdList": ["10.1111/dth.13360", "32239587", "7228325"]}, {"Citation": "Bardazzi F, Loi C, Sacchelli L, Di Altobrando A (2020) Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat 31(4):320\u2013321", "ArticleIdList": ["32248724", "10.1080/09546634.2020.1749545"]}, {"Citation": "Megna M, Ruggiero A, Marasca C, Fabbrocini G (2020) Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat 31(4):328\u2013329", "ArticleIdList": ["32301363", "10.1080/09546634.2020.1757605"]}, {"Citation": "Megna M, Napolitano M, Patruno C, Fabbrocini G (2020) Biologics for psoriasis in COVID-19 era: What do we know? Dermatol Ther 33(4):e13467. https://doi.org/10.1111/dth.13467", "ArticleIdList": ["10.1111/dth.13467", "32338424", "7261982"]}, {"Citation": "Naldi L (2021) Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic. Br J Dermatol 184(1):6. https://doi.org/10.1111/bjd.19190"}, {"Citation": "Kara Polat A, Oguz Topal I, Karadag AS, et al (2021) The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther 34(1):e14691. https://doi.org/10.1111/dth.14691", "ArticleIdList": ["10.1111/dth.14691", "33351215"]}, {"Citation": "Gisondi P, Facheris P, Dapavo P, et al (2020) The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol 183(2):373\u2013374", "ArticleIdList": ["32343839", "7267283", "10.1111/bjd.19158"]}, {"Citation": "Carugno A, Gambini DM, Raponi F, et al (2020) COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol 83(1):292\u2013294", "ArticleIdList": ["32387660", "10.1016/j.jaad.2020.04.165"]}, {"Citation": "Damiani G, Pacifico A, Bragazzi NL, Malagoli P (2020) Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 33(5):e13475. https://doi.org/10.1111/dth.13475", "ArticleIdList": ["10.1111/dth.13475", "32356577", "7261990"]}, {"Citation": "Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367. https://doi.org/10.1136/bcr-2020-237367", "ArticleIdList": ["10.1136/bcr-2020-237367", "32784237", "7418771"]}, {"Citation": "Rouai M, Rabhi F, Mansouri N, et al (2021) New-onset guttate psoriasis secondary to COVID-19. Clin Case Rep 9(7):e04542. https://doi.org/10.1002/ccr3.4542", "ArticleIdList": ["10.1002/ccr3.4542", "34336212", "8319378"]}, {"Citation": "Penso L, Dray-Spira R, Weill A, et al (2022) Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 186(1):59\u201368", "ArticleIdList": ["34310699", "10.1111/bjd.20659"]}, {"Citation": "Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol 85(5):1274\u20131284", "ArticleIdList": ["34363909", "8336973", "10.1016/j.jaad.2021.07.054"]}, {"Citation": "Geisen UM, Berner DK, Tran F, et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80(10):1306\u20131311", "ArticleIdList": ["33762264", "10.1136/annrheumdis-2021-220272"]}, {"Citation": "Simon D, Tascilar K, Fagni F, et al (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80(10):1312\u20131316", "ArticleIdList": ["33958324", "10.1136/annrheumdis-2021-220461"]}, {"Citation": "Skroza N, Bernardini N, Tolino E, et al (2021) Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. J Clin Med 10(15):"}, {"Citation": "Damiani G, Allocco F, Malagoli P (2021) COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol 46(6):1106\u20131108", "ArticleIdList": ["33666256", "8012997", "10.1111/ced.14631"]}, {"Citation": "Gelfand JM, Armstrong AW, Bell S, et al (2021) National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 84(5):1254\u20131268", "ArticleIdList": ["33422626", "7788316", "10.1016/j.jaad.2020.12.058"]}, {"Citation": "Elamin S, Hinds F,Tolland J (2022) De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol 47(1):153\u2013155", "ArticleIdList": ["34398977", "10.1111/ced.14895"]}, {"Citation": "Nagrani P, Jindal R, Goyal D (2021) Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases. Dermatol Ther 34(5):e15085. https://doi.org/10.1111/dth.15085", "ArticleIdList": ["10.1111/dth.15085", "34350668", "8420438"]}, {"Citation": "Song WJ, Lim Y, Jo SJ (2022) De novo guttate psoriasis following coronavirus disease 2019 vaccination. J Dermatol 49(1):e30\u2013e31", "ArticleIdList": ["34713443", "10.1111/1346-8138.16203"]}, {"Citation": "Lehmann M, Schorno P, Hunger RE, et al (2021) New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol 35(11):e752\u2013e755", "ArticleIdList": ["34309932", "8447029", "10.1111/jdv.17561"]}, {"Citation": "Ricardo JW, Lipner SR (2021) Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep 1718\u20131720"}, {"Citation": "Gunes AT, Fetil E, Akarsu S, et al (2015) Possible Triggering Effect of Influenza Vaccination on Psoriasis. J Immunol Res 2015:258430. https://doi.org/10.1155/2015/258430", "ArticleIdList": ["10.1155/2015/258430", "26380315", "4562095"]}, {"Citation": "Wu PC, Huang IH, Wang CW, et al (2022) New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. Am J Clin Dermatol 23(6):775\u2013799", "ArticleIdList": ["36048409", "9434078", "10.1007/s40257-022-00721-z"]}, {"Citation": "Krajewski PK, Matusiak \u0141, Szepietowski JC (2021) Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol 35(10):e632\u2013e634", "ArticleIdList": ["34131967", "8447171"]}, {"Citation": "Durmaz I, Turkmen D, Altunisik N,Toplu SA (2022) Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: A report of three cases. Dermatol Ther 35(4):e15331. https://doi.org/10.1111/dth.15331", "ArticleIdList": ["10.1111/dth.15331", "35066960"]}, {"Citation": "Perna D, Jones J, Schadt CR (2021) Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep 17:1\u20133", "ArticleIdList": ["34522741", "8428031", "10.1016/j.jdcr.2021.08.035"]}, {"Citation": "Phuan CZY, Choi EC-E,Oon HH (2022) Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature. JAAD International 6:94\u201396", "ArticleIdList": ["34957419", "10.1016/j.jdin.2021.11.004"]}, {"Citation": "Mieczkowska K, Kaubisch A,McLellan BN (2021) Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. Dermatol Ther 34(5):e15055. https://doi.org/10.1111/dth.15055", "ArticleIdList": ["10.1111/dth.15055", "34231301", "8420314"]}, {"Citation": "Bostan E, Elmas L, Yel B,Yalici-Armagan B (2021) Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases. Dermatol Ther 34(6):e15110. https://doi.org/10.1111/dth.15110", "ArticleIdList": ["10.1111/dth.15110", "34427024", "8646432"]}, {"Citation": "Fang WC, Chiu LW,Hu SC (2021) Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. J Dermatol 48(11):e566\u2013e567", "ArticleIdList": ["34487570", "8652484", "10.1111/1346-8138.16137"]}, {"Citation": "Koumaki D, Krueger-Krasagakis SE, et al (2022) Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol 36(6):e411\u2013e415", "ArticleIdList": ["35075691", "10.1111/jdv.17965"]}, {"Citation": "Wei N, Kresch M, Elbogen E,Lebwohl M (2022) New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Reports 19:74\u201377", "ArticleIdList": ["34869811", "10.1016/j.jdcr.2021.11.016"]}, {"Citation": "Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D,Vakirlis E (2021) Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol 35(12):e857\u2013e859", "ArticleIdList": ["34363647", "8447325", "10.1111/jdv.17582"]}, {"Citation": "Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A,Fabbrocini G (2022) Reply to \u201cPsoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre\u201d by Sotiriou E et al. Journal of the European Academy of Dermatology and Venereology 36(1):e11\u2013e13"}, {"Citation": "Huang YW, Tsai TF (2021) Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center. Front Med (Lausanne) 8:812010. https://doi.org/10.3389/fmed.2021.812010", "ArticleIdList": ["10.3389/fmed.2021.812010", "35004790"]}, {"Citation": "Onsun N, Kaya G, I\u015f\u0131k BG,G\u00fcne\u015f B (2021) A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect 11(2):261\u2013262", "ArticleIdList": ["34195051", "8233675", "10.34172/hpp.2021.32"]}, {"Citation": "Piccolo V,Russo T,Mazzatenta C,Bassi A,Argenziano G,Cutrone M et al. (2022) COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol 36(5):e330\u2013e332", "ArticleIdList": ["35015916", "10.1111/jdv.17918"]}, {"Citation": "Quattrini L, Verardi L, Caldarola G, Peluso G, De Simone C,D\u2019Agostino M (2021) New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination. J Eur Acad Dermatol Venereol 35(11):e727\u2013e729", "ArticleIdList": ["34236728", "8447202", "10.1111/jdv.17502"]}, {"Citation": "World Health Organization; Types of COVID-19 vaccines. https://www.who.int/westernpacific/emergencies/covid-19/covid-19-vaccines . Accessed October 2022"}, {"Citation": "European Medicines Agency; Adapted COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised . Accessed October 20, 2022"}, {"Citation": "Sbidian E, Eftekahri P, Viguier M, et al (2014) National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines. Dermatology 229(2):130\u2013135", "ArticleIdList": ["25171322", "10.1159/000362808"]}, {"Citation": "Jara LJ, Vera-Lastra O, Mahroum N, et al (2022) Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol 41(5):1603\u20131609", "ArticleIdList": ["35378658", "8979721", "10.1007/s10067-022-06149-4"]}, {"Citation": "Aryanian Z, Balighi K, Afshar ZM, et al (2022) COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic. J Cosmet Dermatol https://doi.org/10.1111/jocd.15448"}, {"Citation": "Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S (2020) Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol 92(4):e12945. https://doi.org/10.1111/sji.12945", "ArticleIdList": ["10.1111/sji.12945", "32697368"]}, {"Citation": "Yuan Y, Qiu J, Lin ZT, et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol 71(6):941\u2013951", "ArticleIdList": ["30618213", "10.1002/art.40830"]}, {"Citation": "POTS/Long Covid-diagnostics; CellTrend; https://www.celltrend.de/en/pots-cfs-me-sfn/ . Accessed September 4, 2022"}, {"Citation": "EUROIMMUN Autoantibodies in neurological diseases. https://www.euroimmun.com/documents/Indications/Autoimmunity/Neurology/MAG_myelin_GAD/FA_1111_I_UK_A.pdf . Accessed September 4, 2022"}, {"Citation": "Guest PC, Abbasifard M, Jamialahmadi T, et al (2022) Multiplex Immunoassay for Prediction of Disease Severity Associated with the Cytokine Storm in COVID-19 Cases. Methods Mol Biol 2511:245\u2013256", "ArticleIdList": ["35838965", "10.1007/978-1-0716-2395-4_18"]}, {"Citation": "Zahedipour F, Guest PC, Majeed M, et al (2022) Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis. Methods Mol Biol 2511:285\u2013295", "ArticleIdList": ["35838968", "10.1007/978-1-0716-2395-4_21"]}, {"Citation": "Einhorn L, Krapfenbauer K (2015) HTRF: a technology tailored for biomarker determination-novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids. EPMA J 6:23. https://doi.org/10.1186/s13167-015-0046-y", "ArticleIdList": ["10.1186/s13167-015-0046-y", "26617680", "4662825"]}, {"Citation": "Peter H, Wienke J, Bier FF (2017) Lab-on-a-Chip Multiplex Assays. Methods Mol Biol 1546:283\u2013294", "ArticleIdList": ["27896778", "10.1007/978-1-4939-6730-8_25"]}, {"Citation": "Peter H, Mattig E, Guest PC, Bier FF (2022) Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease. Methods Mol Biol 2511:235\u2013244", "ArticleIdList": ["35838964", "10.1007/978-1-0716-2395-4_17"]}, {"Citation": "European Medicines Agency; Safety of COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines . Accessed October 20, 2022"}, {"Citation": "McMahon DE, Amerson E, Rosenbach M, et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 85(1):46\u201355", "ArticleIdList": ["33838206", "8024548", "10.1016/j.jaad.2021.03.092"]}, {"Citation": "Catal\u00e0 A, Mu\u00f1oz-Santos C, Galv\u00e1n-Casas C, et al (2022) Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 186(1):142\u2013152", "ArticleIdList": ["34254291", "10.1111/bjd.20639"]}, {"Citation": "Cebeci Kahraman F, Sava\u015f Erdo\u011fan S, et al (2022) Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study. J Cosmet Dermatol 21(9):3692\u20133703", "ArticleIdList": ["35780311", "10.1111/jocd.15209"]}, {"Citation": "Bostan E, Yel B, Karaduman A (2022) Cutaneous adverse events following 771 doses of the inactivated and mRNA COVID-19 vaccines: A survey study among health care providers. J Cosmet Dermatol 21(9):3682\u20133688", "ArticleIdList": ["35775860", "10.1111/jocd.15203"]}, {"Citation": "Falotico JM, Desai AD, Shah A, et al (2022) Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database. Am J Clin Dermatol 23(5):729\u2013737", "ArticleIdList": ["35931925", "9361907", "10.1007/s40257-022-00715-x"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "6", "Day": "30", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "13", "Minute": "8"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "11", "Minute": "7"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37378776", "10.1007/978-3-031-28012-2_18"]}}], "PubmedBookArticle": []}